Difference between revisions of "Template:Oral hypoglycemics and insulin analogs"
From Self-sufficiency
(nav) |
m (1 revision: World Health Organization essential medicines) |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 41: | Line 41: | ||
| group3 = [[Glucagon-like peptide-1 analog|GLP-1 analogs]] | | group3 = [[Glucagon-like peptide-1 analog|GLP-1 analogs]] | ||
| − | | list3 = [[Exenatide]]{{·}}[[Liraglutide]]{{·}}[[Taspoglutide]]<sup>†</sup>{{·}}[[Albiglutide]]<sup>†</sup> | + | | list3 = [[Exenatide]]{{·}}[[Liraglutide]]{{·}}[[Taspoglutide]]<sup>†</sup>{{·}}[[Albiglutide]]<sup>†</sup>{{·}}[[Lixisenatide]] |
| group4 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s | | group4 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s | ||
| Line 62: | Line 62: | ||
| list8 = [[Pramlintide]] | | list8 = [[Pramlintide]] | ||
| − | | group11 = [[Sodium-glucose transport proteins|SGLT2]] | + | | group11 = [[Sodium-glucose transport proteins|SGLT2]] inhibitors |
| − | | list11 = [[Dapagliflozin]]<sup>†</sup>{{·}}[[Remogliflozin etabonate|Remogliflozin]]<sup>†</sup>{{·}}[[Sergliflozin etabonate|Sergliflozin]]<sup>†</sup> | + | | list11 = [[Canagliflozin]]<sup>†</sup>{{·}} [[Dapagliflozin]]<sup>†</sup>{{·}} [[Remogliflozin etabonate|Remogliflozin]]<sup>†</sup>{{·}} [[Sergliflozin etabonate|Sergliflozin]]<sup>†</sup> |
| group12 = Other | | group12 = Other | ||
| Line 78: | Line 78: | ||
[[Category:Drug templates|{{PAGENAME}}]] | [[Category:Drug templates|{{PAGENAME}}]] | ||
</noinclude> | </noinclude> | ||
| − | |||
Latest revision as of 15:53, 27 September 2010
Lua error in package.lua at line 80: module 'Module:Color contrast' not found.
